Libersan D - Search Results

1

Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents.

Eisenberg MJ, Richard PR, Libersan D, Filion KB. Eisenberg MJ, et al. Among authors: libersan d. Circulation. 2009 Mar 31;119(12):1634-42. doi: 10.1161/CIRCULATIONAHA.108.813667. Epub 2009 Mar 16. Circulation. 2009. PMID: 19289638 Review.

2

A comprehensive view of sex-specific issues related to cardiovascular disease.

Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C, Rabi D, Tremblay J, Alamian A, Barnett T, Cox J, Ghali WA, Grace S, Hamet P, Ho T, Kirkland S, Lambert M, Libersan D, O'Loughlin J, Paradis G, Petrovich M, Tagalakis V. Pilote L, et al. Among authors: libersan d. CMAJ. 2007 Mar 13;176(6):S1-44. doi: 10.1503/cmaj.051455. CMAJ. 2007. PMID: 17353516 Free PMC article. Review.

3

Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1.

Tanguay JF, Geoffroy P, Sirois MG, Libersan D, Kumar A, Schaub RG, Merhi Y. Tanguay JF, et al. Among authors: libersan d. Thromb Haemost. 2004 Jun;91(6):1186-93. doi: 10.1160/TH03-11-0701. Thromb Haemost. 2004. PMID: 15175806

4

Platelet P-selectin expression: requirement for protein kinase C, but not protein tyrosine kinase or phosphoinositide 3-kinase.

Libersan D, Merhi Y. Libersan D, et al. Thromb Haemost. 2003 Jun;89(6):1016-23. Thromb Haemost. 2003. PMID: 12783114

5

Atrial ischemia promotes atrial fibrillation in dogs.

Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S. Sinno H, et al. Among authors: libersan d. Circulation. 2003 Apr 15;107(14):1930-6. doi: 10.1161/01.CIR.0000058743.15215.03. Epub 2003 Mar 31. Circulation. 2003. PMID: 12668526

6

Differential regulation of P-selectin expression by protein kinase A and protein kinase G in thrombin-stimulated human platelets.

Libersan D, Rousseau G, Merhi Y. Libersan D, et al. Thromb Haemost. 2003 Feb;89(2):310-7. Thromb Haemost. 2003. PMID: 12574812

7

Intravenous aspirin at reperfusion does not reduce infarct size in the dog with a residual critical stenosis.

Libersan D, Quan E, Merhi Y, Uzan A, Laperrière L, Latour JG. Libersan D, et al. J Cardiovasc Pharmacol. 1999 Oct;34(4):575-83. doi: 10.1097/00005344-199910000-00015. J Cardiovasc Pharmacol. 1999. PMID: 10511134

8

The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog.

Libersan D, Khalil A, Dagenais P, Quan E, Delorme F, Uzan A, Latour JG. Libersan D, et al. Cardiovasc Res. 1998 Mar;37(3):656-66. doi: 10.1016/s0008-6363(97)00292-7. Cardiovasc Res. 1998. PMID: 9659449

9

Cardioprotective effects of diltiazem during acute rejection on heterotopic heart transplants.

Libersan D, Marchand R, Montplaisir S, Chartrand C, Dumont L. Libersan D, et al. Eur Surg Res. 1997;29(3):229-36. doi: 10.1159/000129528. Eur Surg Res. 1997. PMID: 9161840

10

Importance of platelets in myocardial injury after reperfusion in the presence of residual coronary stenosis in dogs.

Rousseau G, Hébert D, Libersan D, Khalil A, St-Jean G, Latour JG. Rousseau G, et al. Among authors: libersan d. Am Heart J. 1993 Jun;125(6):1553-63. doi: 10.1016/0002-8703(93)90740-z. Am Heart J. 1993. PMID: 8498293

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10 results

Search Page